BACKGROUND: The management of patients with relapsed or refractory Hodgkin's lymphoma who achieve less than a partial response to first-line salvage chemotherapy is unclear. The objective of this study was to evaluate response and outcomes to second-line salvage and autologous stem cell transplantation in patients not achieving a complete or partial response to platinum-containing first-line salvage chemotherapy. DESIGN AND METHODS: Consecutively referred transplant-eligible patients with relapsed/refractory Hodgkin's lymphoma after primary chemotherapy received gemcitabine, dexamethasone, and cisplatin as first salvage chemotherapy. Those achieving a complete or partial response, and those with a negative gallium scan and stable disease with bulk <5 cm proceeded to high-dose chemotherapy and autologous stem cell transplantation. Patients with progressive disease or stable disease with a positive gallium scan or bulk ≥ 5 cm were given second salvage chemotherapy with mini-BEAM (carmustine, etoposide, cytarabine, melphalan). Patients who responded (according to the same definition) proceeded to autologous stem cell transplantation. RESULTS: One hundred and thirty-one patients with relapsed/refractory Hodgkin's lymphoma received first-line salvage gemcitabine, dexamethasone, and cisplatin; of these patients 99 had at least a partial response (overall response rate 76%). One hundred and twelve (85.5%) patients proceeded to autologous stem cell transplantation, while the remaining 19 (14.5%) patients received mini-BEAM. Among these 19 patients, six had at least a partial response (overall response rate 32%), and nine proceeded to autologous stem cell transplantation. The remaining ten patients received palliative care. Seven of the nine patients transplanted after mini-BEAM had a subsequent relapse. Patients receiving second salvage mini-BEAM had poor outcomes, with a 5-year progression-free survival rate of 11% and a 5-year overall survival rate of 20%. CONCLUSIONS: Patients who require a second salvage regimen to achieve disease control prior to autologous stem cell transplantation have a relatively poor outcome and should be considered for alternative treatment strategies.
BACKGROUND: The management of patients with relapsed or refractory Hodgkin's lymphoma who achieve less than a partial response to first-line salvage chemotherapy is unclear. The objective of this study was to evaluate response and outcomes to second-line salvage and autologous stem cell transplantation in patients not achieving a complete or partial response to platinum-containing first-line salvage chemotherapy. DESIGN AND METHODS: Consecutively referred transplant-eligible patients with relapsed/refractory Hodgkin's lymphoma after primary chemotherapy received gemcitabine, dexamethasone, and cisplatin as first salvage chemotherapy. Those achieving a complete or partial response, and those with a negative gallium scan and stable disease with bulk <5 cm proceeded to high-dose chemotherapy and autologous stem cell transplantation. Patients with progressive disease or stable disease with a positive gallium scan or bulk ≥ 5 cm were given second salvage chemotherapy with mini-BEAM (carmustine, etoposide, cytarabine, melphalan). Patients who responded (according to the same definition) proceeded to autologous stem cell transplantation. RESULTS: One hundred and thirty-one patients with relapsed/refractory Hodgkin's lymphoma received first-line salvage gemcitabine, dexamethasone, and cisplatin; of these patients 99 had at least a partial response (overall response rate 76%). One hundred and twelve (85.5%) patients proceeded to autologous stem cell transplantation, while the remaining 19 (14.5%) patients received mini-BEAM. Among these 19 patients, six had at least a partial response (overall response rate 32%), and nine proceeded to autologous stem cell transplantation. The remaining ten patients received palliative care. Seven of the nine patients transplanted after mini-BEAM had a subsequent relapse. Patients receiving second salvage mini-BEAM had poor outcomes, with a 5-year progression-free survival rate of 11% and a 5-year overall survival rate of 20%. CONCLUSIONS:Patients who require a second salvage regimen to achieve disease control prior to autologous stem cell transplantation have a relatively poor outcome and should be considered for alternative treatment strategies.
Authors: B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos Journal: J Clin Oncol Date: 1999-04 Impact factor: 44.544
Authors: Karl S Peggs; Ann Hunter; Rajesh Chopra; Anne Parker; Premini Mahendra; Donald Milligan; Charles Craddock; Ruth Pettengell; Ahmet Dogan; Kirsty J Thomson; Emma C Morris; Geoff Hale; Herman Waldmann; Anthony H Goldstone; David C Linch; Stephen Mackinnon Journal: Lancet Date: 2005 Jun 4-10 Impact factor: 79.321
Authors: A Nademanee; M R O'Donnell; D S Snyder; G M Schmidt; P M Parker; A S Stein; E P Smith; A Molina; D E Stepan; G Somlo Journal: Blood Date: 1995-03-01 Impact factor: 22.113
Authors: D C Linch; D Winfield; A H Goldstone; D Moir; B Hancock; A McMillan; R Chopra; D Milligan; G V Hudson Journal: Lancet Date: 1993-04-24 Impact factor: 79.321
Authors: J Rodriguez; M A Rodriguez; L Fayad; P McLaughlin; F Swan; A Sarris; J Romaguera; B Andersson; F Cabanillas; F B Hagemeister Journal: Blood Date: 1999-06-01 Impact factor: 22.113
Authors: Elias Jabbour; Chitra Hosing; Gregory Ayers; Rodolfo Nunez; Paolo Anderlini; Barbara Pro; Issa Khouri; Anas Younes; Fredrick Hagemeister; Larry Kwak; Luis Fayad Journal: Cancer Date: 2007-06-15 Impact factor: 6.860
Authors: Henry C Fung; Patrick Stiff; Jeff Schriber; Amir Toor; Eileen Smith; Tulio Rodriguez; Amrita Krishnan; Arturo Molina; David Smith; Barbara Ivers; Neil Kogut; Leslie Popplewell; Roberto Rodriguez; George Somlo; Stephen J Forman; Auayporn Nademanee Journal: Biol Blood Marrow Transplant Date: 2007-03-23 Impact factor: 5.742
Authors: Scott F Huntington; Gottfried von Keudell; Amy J Davidoff; Cary P Gross; Sapna A Prasad Journal: J Clin Oncol Date: 2018-10-04 Impact factor: 44.544
Authors: Reid W Merryman; Robert A Redd; Taiga Nishihori; Julio Chavez; Yago Nieto; Justin M Darrah; Uttam Rao; Michael T Byrne; David A Bond; Kami J Maddocks; Michael A Spinner; Ranjana H Advani; Hatcher J Ballard; Jakub Svoboda; Anurag K Singh; Joseph P McGuirk; Dipenkumar Modi; Radhakrishnan Ramchandren; Jason Romancik; Jonathon B Cohen; Matthew J Frigault; Yi-Bin Chen; Anthony V Serritella; Justine Kline; Stephen Ansell; Sunita Nathan; Maryam Rahimian; Robin M Joyce; Mansi Shah; Kevin A David; Steven Park; Anne W Beaven; Alma Habib; Veronika Bachanova; Shazia Nakhoda; Nadia Khan; Ryan C Lynch; Stephen D Smith; Vincent T Ho; Ann LaCasce; Philippe Armand; Alex F Herrera Journal: Blood Adv Date: 2021-03-23
Authors: Pier Luigi Zinzani; Radhakrishnan Ramchandren; Armando Santoro; Ewa Paszkiewicz-Kozik; Robin Gasiorowski; Nathalie A Johnson; Jose S R de Oliveira; Valeria Buccheri; Guilherme Fleury Perini; Michael Dickinson; Andrew McDonald; Muhit Özcan; Naohiro Sekiguchi; Ying Zhu; Monika Raut; Todd L Saretsky; Akash Nahar; John Kuruvilla Journal: Blood Adv Date: 2022-01-25
Authors: Richard Greil; Lisa Pleyer; Bettina Jansko; Carmen Feierabend; Lukas Rettenbacher; Olga Stiefel; Christoph Rass; Patrick Morre; Daniel Neureiter; Sigrun Greil-Ressler Journal: Oncotarget Date: 2018-04-17